Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform
10.24171/j.phrp.2021.0311
- Author:
Jung Hun JU
1
;
Naery LEE
;
Sun-hee KIM
;
Seokkee CHANG
;
Misook YANG
;
Jihyun SHIN
;
Eunjo LEE
;
Sunhwa SUNG
;
Jung-Hwan KIM
;
Jin Tae HONG
;
Ho Jung OH
Author Information
1. Emerging Infectious Disease Vaccines Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Korea
- Publication Type:Review Article
- From:
Osong Public Health and Research Perspectives
2022;13(1):4-14
- CountryRepublic of Korea
- Language:English
-
Abstract:
Due to the global public health crisis caused by the coronavirus disease 2019 (COVID-19) pandemic, the importance of vaccine development has increased. In particular, a rapid supply of vaccines and prompt deployment of vaccination programs are essential to prevent and overcome the spread of COVID-19. As a part of the vaccine regulations, national lot release is regulated by the responsible authorities, and this process involves the assessment of the lot before a vaccine is marketed. A lot can be released for use when both summary protocol (SP) review and quality control testing are complete. Accelerated lot release is required to distribute COVID-19 vaccines in a timely manner. In order to expedite the process by simultaneously undertaking the verification of quality assessment and application for approval, it is necessary to prepare the test methods before marketing authorization. With the prolonged pandemic and controversies regarding the effectiveness of the COVID-19 vaccine against new variants, public interest for the development of a new vaccine are increasing. Domestic developers have raised the need to establish standard guidance on the requirements for developing COVID-19 vaccine. This paper presents considerations for quality control in the manufacturing process, test items, and SP content of viral vector vaccines.
